Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Abstract: 3-path vertex cover of networks is a typical optimization problem in network science, which has a wide range of applications. Toward a 3-path vertex cover of networks from distributed ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...

Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...

Google Cloud expanded features of its Agent Builder platform focusing on orchestration, observability and monitoring for the ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...